Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma

摘要

MYD88 L265P, a diagnostic marker for lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglob-ulinemia (WM) can also be detected in other hematopoietic malignancies. We demonstrate a novel approach to increase the specificity of this marker for WM/LPL diagnosis by combining flow cytometric cell sorting with molecular analysis.